

## Addendum

**Addendum: Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition****Marcel Kemper<sup>1,2,\*</sup>, Georg Evers<sup>1,2,\*</sup>, Arik Bernard Schulze<sup>1,2</sup>, Jan Sperveslage<sup>3</sup>, Christoph Schülke<sup>4</sup>, Georg Lenz<sup>1,2</sup>, Thomas Herold<sup>5</sup>, Wolfgang Hartmann<sup>3</sup>, Hans-Ulrich Schildhaus<sup>2,5,#</sup> and Annalen Bleckmann<sup>1,2,6,#</sup>**<sup>1</sup>Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Muenster, 48149 Muenster, Germany<sup>2</sup>West German Cancer Center, Sites Muenster & Essen, 45147 Essen, Germany<sup>3</sup>Gerhard-Domagk-Institute of Pathology, University Hospital Muenster, 48149 Muenster, Germany<sup>4</sup>Institute of Clinical Radiology, University Hospital Muenster, 48149 Muenster, Germany<sup>5</sup>Institute of Pathology, University Hospital Essen, 45147 Essen, Germany<sup>6</sup>Department of Hematology/Medical Oncology, University Medical Center Goettingen, 37075 Goettingen, Germany

\* Authors share first authorship

# Authors share last authorship

**Published:** November 02, 2022**Copyright:** © 2022 Kemper et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.**This article has an addendum:** The authors obtained written informed consent from the patient to publish information and images.Original article: Oncotarget. 2021; 12:1946–1952. <https://doi.org/10.18632/oncotarget.28062>